Chapter 3 | Financing in Biotechnology

[3.1] Types of Biotech Financing – Founding of Company to Product Approval11/
[3.2] Overall Financing of Public Biotech Companies, (2003-2020)119
[3.3] Financing in Biotechnology – IPOs – Total \$B & Number (2010-2020)120
[3.4] Partnership and Total Financing for Biotech Companies (2002-2007-2012-2017) in 5-Year Intervals
[3.5.1] Biotech Financing - Venture Capital & Follow-on Stock Offering in \$ Billions (2003-2020)
[3.5.2] Biotech Financing – Debt in \$ Billions (2003-2020)122
[3.6.1, 3.6.2] R&D Funding - Public Biotech Companies with minimum of \$100 million for the years (2001-2017)
[3.6.1] Financing by Biotech Companies in R&D, Totals in Billions USD in 5-Year Intervals (2001-2020)
[3.6.2] Financing in R&D by Biotech Companies, Total Amounts for Individual Years (2001-2020)
[3.7.1 – 3.7.4] R & D Investment by Top Worldwide Public Biotech Companies over Time (2001-2020)125
[3.7.1] R & D Investment by Top Worldwide Public Biotech Companies over Time (2001-2005)
[3.7.2] R & D Investment by Top Worldwide Public Biotech Companies, at least \$100 million, over Time (2006-2010)
[3.7.3] R & D Investment by Top Worldwide Public Biotech Companies, at least \$100 million, over Time (2011-2015)
[3.7.4] R & D Investment by Worldwide Public Biotech Companies over Time, at least \$100 million in one year (2016 - 2020)
[3.8] Financing – R&D Budgets – Worldwide Public Biotech Companies (2001-2020)134
[3.9.1 -3.9.3] Worldwide Pharma R&D Spend Estimates on Biotech in \$ USD (2001-2020)136

[3.9.1] Worldwide Pharma R&D Spend Estimates in Biotech \$ USD (2001-2006)	137
[3.9.2] Worldwide Pharma R&D Spend Estimates in Biotech \$ USD (2007-2012)	138
[3.9.3] Worldwide Pharma R&D Spend Estimates in Biotech \$ USD (2013-2018)	139
[3.9.4] Worldwide Pharma R&D Spend Estimates in Biotech \$ USD (2019-2020)	140